Intermittent fasting diets have become very popular in the past few years, as they can produce clinically significant weight loss. These diets can be defined, in the simplest of terms, as periods of fasting alternating with periods of eating. The most studied forms of intermittent fasting include...
the prevalence and clinical impact of weight loss in these patients still need to be elucidated. This retrospective single-center study reviewed 134 consecutive patients diagnosed with IPF. Weight loss of 5% or more over 1 year was defined as significant weight loss. ...
Sixty one residents had significant weight loss during one out of the four months. Twenty two residents has significant weight loss in two or more months during the study. The pre-selected variables were gathered through a chart review on the subjects which had significant unintentional weight ...
CIMWM was shown to be superior to TMWM in the improvement of clinically-significant weight loss, BMI, total cholesterol (TC), the body composition parameters BFM and the skeletal muscle mass-to-visceral fat area ratio (S/V) (p < 0.05). The non-alcoholic fatty liver disease score (...
After 16 weeks, patients randomized to the LED group had experienced a mean weight change of −15.8 kg compared with −0.4 kg in the control group. Thus, there was a statistically significant mean difference in weight loss between the 2 groups of 15.4 kg (95% CI, 12.3-18.5 kg; P...
10 and the long-term public health benefits of an effective treatment for OA and obesity-related complications,11 we tested the hypothesis that achieving sustained, significant weight loss, with or without increased exercise, would reduce joint loading and inflammation and improve clinical outcomes ...
A significant loss of TBS (− 2.4%) and BMD (− 1.7%) was demonstrated in women receiving the placebo, whereas in women treated with risedronate, there was no change in TBS and an increase in BMD (2.3%). Similar findings were reported in osteopenic/osteoporotic men and women ...
There were no statistically significant differences between the two groups after switching for the other tolerability outcomes (loss of libido, impotence/sexual dysfunction and weight change). Table 4 The impact on clinical outcomes of switching to risperidone, compared with switching to olanzapine ...
Previous analyses of clinical and physiological parameters had shown that these two groups (responders and non-responders) are comparable at baseline in term of weight and insulin sensitivity (Fig. 1D). Upon LCD, both groups had achieved significant weight loss (>8% initial body weight); yet th...
Mazdutide is a once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist. Here, the authors show mazdutide was well tolerated over 24 weeks and demonstrated significant and clinically meaningful body weight loss, compared with placebo, in Chinese overweight adults or adults...